Domača stranBIOG-B • STO
add
BioGaia
Prejšnji trg. dan.
108,40 kr
Dnevni razpon
107,20 kr - 108,80 kr
Letni razpon
93,45 kr - 136,60 kr
Tržna kapitalizacija
10,56 mrd. SEK
Povprečni obseg
318,34 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
STO
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (SEK) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 384,12 mio. | 21,86 % |
Stroški poslovanja | 142,86 mio. | 2,14 % |
Čisti dohodek | 111,01 mio. | 37,82 % |
Čista dobičkovnost prihodkov | 28,90 | 13,11 % |
Earnings per share | — | — |
EBITDA | 147,33 mio. | 58,38 % |
Efektivna davčna stopnja | 22,24 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (SEK) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 1,01 mrd. | −26,42 % |
Skupna sredstva | 1,90 mrd. | −11,88 % |
Skupne obveznosti | 325,40 mio. | 19,08 % |
Celoten lastniški kapital | 1,58 mrd. | — |
Shares outstanding | 100,98 mio. | — |
Razmerje P/B | 6,95 | — |
Donosnost sredstev | 16,11 % | — |
Donosnost kapitala | 18,86 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (SEK) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 111,01 mio. | 37,82 % |
Denar iz dejavnosti | 119,12 mio. | 13,94 % |
Denar iz naložb | −2,24 mio. | 90,87 % |
Denar iz financiranja | −699,12 mio. | −136,40 % |
Neto sprememba denarnih sredstev | −583,65 mio. | −176,28 % |
Prost denarni tok | 100,27 mio. | 67,38 % |
Vizitka
BioGaia is a Swedish biotechnology company that develops, markets and sells a range of probiotic products. It has patented the use of several Lactobacillus reuteri strains and offers gut and immune health products containing L. reuteri Protectis. Their oral health products contain L. reuteri Prodentis, a blend of the L. reuteri strains DSM 17938 and ATCC PTA 5289. Products containing L. reuteri have been proven to be both effective and safe in several applications: infant colic, diarrhea prevention and mitigation in children, eradication of H. pylori infection and reduction of side effects from standard H. pylori treatment, amelioration of gingivitis, and general illness prevention in children and adults. BioGaia was ranked 9th in the Top 30 Global Probiotic Food Ingredient Companies list by FoodTalks in 2021. The BioGaia -B share is listed on the NASDAQ OMX Nordic Exchange. Wikipedia
Generalni direktor
Datum ustanovitve
1990
Spletno mesto
Zaposleni
220
